Log in

LON:MPH - Mereo BioPharma Group Share Price, Forecast & News

GBX 37
0.00 (0.00 %)
(As of 12/6/2019 04:00 PM ET)
Today's Range
Now: GBX 37
50-Day Range
MA: GBX 44.32
52-Week Range
Now: GBX 37
Volume5,228 shs
Average Volume266 shs
Market Capitalization£36.25 million
P/E RatioN/A
Dividend YieldN/A
Mereo BioPharma Group plc, a specialty biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of rare and specialty diseases. Its product candidates include BPS-804, a monoclonal antibody, which is in Phase IIb clinical trial for the treatment of osteogenesis imperfecta; AZD-9668, an oral small molecule that has been completed Phase I clinical trial to treat Alpha-1 antitrypsin deficiency; BGS-649, an oral aromatase inhibitor, which is in Phase IIb clinical trial for the treatment of hypogonadal hypogonadism; and BCT-197, an oral p38 MAP kinase inhibitor that is in Phase II clinical trial to treat acute exacerbations of chronic obstructive pulmonary disease. Read More…

Industry, Sector and Symbol

Industry Biotechnology
Phone44 33 3023 7300



Sales & Book Value

Annual SalesN/A
Cash FlowGBX 36.90 per share
Book ValueGBX 60.30 per share



Market Cap£36.25 million
Next Earnings DateN/A
OptionableNot Optionable

Receive MPH News and Ratings via Email

Sign-up to receive the latest news and ratings for MPH and its competitors with MarketBeat's FREE daily newsletter.

Mereo BioPharma Group (LON:MPH) Frequently Asked Questions

What is Mereo BioPharma Group's stock symbol?

Mereo BioPharma Group trades on the London Stock Exchange (LON) under the ticker symbol "MPH."

Has Mereo BioPharma Group been receiving favorable news coverage?

Media headlines about MPH stock have been trending somewhat positive this week, InfoTrie reports. The research firm ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Mereo BioPharma Group earned a coverage optimism score of 0.7 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Mereo BioPharma Group.

Who are some of Mereo BioPharma Group's key competitors?

What other stocks do shareholders of Mereo BioPharma Group own?

Who are Mereo BioPharma Group's key executives?

Mereo BioPharma Group's management team includes the folowing people:
  • Dr. Denise Scots-Knight, Co-Founder, Chief Exec. Officer & Exec. Director (Age 60)
  • Mr. Richard Crispin Morgan Jones, CFO & Exec. Director (Age 53)
  • Mr. Charles Sermon, Co-Founder, Gen. Counsel & Company Sec. (Age 50)
  • Dr. Alastair MacKinnon, Co-Founder & Chief Medical Officer (Age 49)
  • Mr. John Richard, Co-Founder & Head of Corp. Devel. (Age 62)

How do I buy shares of Mereo BioPharma Group?

Shares of MPH and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Mereo BioPharma Group's stock price today?

One share of MPH stock can currently be purchased for approximately GBX 37.

How big of a company is Mereo BioPharma Group?

Mereo BioPharma Group has a market capitalization of £36.25 million. Mereo BioPharma Group employs 31 workers across the globe.View Additional Information About Mereo BioPharma Group.

What is Mereo BioPharma Group's official website?

The official website for Mereo BioPharma Group is http://mereobiopharma.com/.

How can I contact Mereo BioPharma Group?

Mereo BioPharma Group's mailing address is 1 Cavendish Place, LONDON, W1G 0QF, United Kingdom. The company can be reached via phone at 44 33 3023 7300.

MarketBeat Community Rating for Mereo BioPharma Group (LON MPH)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  112 (Vote Outperform)
Underperform Votes:  87 (Vote Underperform)
Total Votes:  199
MarketBeat's community ratings are surveys of what our community members think about Mereo BioPharma Group and other stocks. Vote "Outperform" if you believe MPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/7/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel